| Id: | acc1604 |
| Group: | 2sens |
| Protein: | DDR1 |
| Gene Symbol: | DDR1 |
| Protein Id: | Q08345 |
| Protein Name: | DDR1_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr792 |
| Site Sequence: | ADFGMSRNLYAGDYYRVQGRA |
| Disease Category: | Cancer |
| Disease: | Colorectal Cancer |
| Disease Subtype: | |
| Disease Cellline: | HCT116 |
| Disease Info: | |
| Drug: | dapagliflozin |
| Drug Info: | "Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by Bristol-Myers Squibb and AstraZeneca, approved for the treatment of type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease, with initial approval by the European Medicines Agency in 2012." |
| Effect: | modulate |
| Effect Info: | The drug reduces the tyrosine phosphorylation of Y792 in DDR1. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 31979355 |
| Sentence Index: | 31979355_12-13 |
| Sentence: | "Dapagliflozin treatment also significantly reduced Y792 tyrosine phosphorylation of DDR1 leading to decrement of DDR1 function and detachment of cancer cells. Concomitant with these lines of results, we experienced that CEA in patients with colon cancer, which express SGLT2 but not UGT1A9, and type 2 diabetes mellitus treated by dapagliflozin in addition to chemotherapy was decreased (case 1)." |
Sequence & Structure:
MGPEALSSLLLLLLVASGDADMKGHFDPAKCRYALGMQDRTIPDSDISASSSWSDSTAARHSRLESSDGDGAWCPAGSVFPKEEEYLQVDLQRLHLVALVGTQGRHAGGLGKEFSRSYRLRYSRDGRRWMGWKDRWGQEVISGNEDPEGVVLKDLGPPMVARLVRFYPRADRVMSVCLRVELYGCLWRDGLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQLADGVVGLDDFRKSQELRVWPGYDYVGWSNHSFSSGYVEMEFEFDRLRAFQAMQVHCNNMHTLGARLPGGVECRFRRGPAMAWEGEPMRHNLGGNLGDPRARAVSVPLGGRVARFLQCRFLFAGPWLLFSEISFISDVVNNSSPALGGTFPPAPWWPPGPPPTNFSSLELEPRGQQPVAKAEGSPTAILIGCLVAIILLLLLIIALMLWRLHWRRLLSKAERRVLEEELTVHLSVPGDTILINNRPGPREPPPYQEPRPRGNPPHSAPCVPNGSALLLSNPAYRLLLATYARPPRGPGPPTPAWAKPTNTQAYSGDYMEPEKPGAPLLPPPPQNSVPHYAEADIVTLQGVTGGNTYAVPALPPGAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTAC| DDR1-Tyr792 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | 0.936 |
| ccRCC | |
| GBM | -1.054 |
| HNSC | |
| LUAD | |
| LUSC | 0.118 |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | P | Breast cancer/tumor/carcinoma | Phosphorylation | 11493640 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
